The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tumour necrosis factor α inhibitors in the treatment of childhood uveitis
Abstract
OBJECTIVE: To describe the efficacy of anti-TNF-alpha agents in the treatment of childhood uveitis. METHODS: We performed a retrospective chart review of all children with uveitis treated with TNF-alpha blockers at The Hospital for Sick Children, Toronto. RESULTS: Twenty-one children with uveitis were treated with the anti-TNF-alpha agents etanercept (11 patients) and infliximab (13 patients), resulting in 24 treatment courses. All patients had persistently active uveitis despite treatment with at least one standard immunosuppressive drug before the start of anti-TNF-alpha therapy. Six of 21 patients (29%) had idiopathic uveitis. In the other 15 patients, the underlying disease was juvenile idiopathic arthritis in 12 (57%), Behçet disease in two (9%) and sarcoidosis in one (5%). Response to etanercept treatment was good in 27%, moderate in 27% and poor in 45% of patients. Response to infliximab treatment was good in 38%, moderate in 54% and poor in 8% of patients. The difference in the percentage of patients with a moderate or good response was statistically significant (P = 0.0481). We also observed a lower rate of complications, such as new-onset or worsening glaucoma or cataract in the infliximab-treated group. CONCLUSION: Anti-TNF-alpha treatment was beneficial in a high percentage of patients with childhood uveitis refractory to standard immunosuppressive treatment. Infliximab resulted in better clinical responses with less ocular complications than etanercept.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baltatzis, S., Tufail, F., Yu, E. N., Vredeveld, C. M., & Foster, C. S. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00092-7 · Cited by 141
Cited by
Ravelli, A., & Martini, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60363-8 · Cited by 1,993
Extraintestinal Manifestations of Inflammatory Bowel Disease
Vavricka, S. R., Schoepfer, A., Scharl, M., Lakatos, P. L., Navarini, A., & Rogler, G. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000392 · Cited by 909
Levy-Clarke, G., Jabs, D. A., Read, R. W., Rosenbaum, J. T., Vitale, A., & Van Gelder, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.048 · Cited by 483
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
Ramanan, A. V., Dick, A. D., Jones, A. P., McKay, A., Williamson, P. R., Compeyrot-Lacassagne, S., Hardwick, B., Hickey, H., Hughes, D., Woo, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614160 · Cited by 437
Juvenile Idiopathic Arthritis: Will Etanercept be an Improvement over Current Therapies?
De Benedetti, F., & Ravelli, A. (2000) · BioDrugs · doi:10.2165/00063030-200014020-00003 · Cited by 428
Metadata
- Authors
- Saurenmann, R. K., Levin, A. V., Rose, J. B., Parker, S., Rabinovitch, T., Tyrrell, P. N., Feldman, B. M., Laxer, R. M., Schneider, R., & Silverman, E. D.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-03
- Volume
- 45
- Issue
- 8
- Pages
- 982-989
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2124151296
- Cited by
- 216
- References
- 1
- FWCI
- 16.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. https://app.cochat.ai/papers/10.1093/rheumatology/kel030
- The paper
- Saurenmann, R. K., Levin, A. V., Rose, J. B., Parker, S., Rabinovitch, T., Tyrrell, P. N., Feldman, B. M., Laxer, R. M., Schneider, R., & Silverman, E. D. (2006). Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology. https://doi.org/10.1093/rheumatology/kel030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.